What is a characteristic of follicular thyroid carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Follicular Thyroid Carcinoma: Key Characteristics

Follicular thyroid carcinoma (FTC) spreads via the hematogenous route, making it distinct from other thyroid cancer types in its metastatic pattern. 1

Epidemiology and Classification

  • FTC is the second most common thyroid cancer after papillary thyroid carcinoma (PTC), not the most common 1, 2
  • Incidence rates for FTC have remained relatively stable over the past 30 years, unlike the rising rates of PTC 1
  • The WHO classifies FTC into three categories based on invasion pattern:
    • Minimally invasive: capsular penetration without vascular involvement (excellent prognosis) 1
    • Angioinvasive: neoplastic emboli involving <4 blood vessels 1
    • Widely invasive: neoplastic emboli involving ≥4 blood vessels or broad areas of transcapsular invasion 1, 3

Diagnostic Challenges

  • FTC cannot be readily diagnosed with fine-needle aspiration (FNA) cytology alone 1
  • FTC is typically classified as "indeterminate" in thyroid cytology reporting schemes 1
  • Definitive diagnosis requires histological evidence of capsular and/or vascular invasion, which can only be determined after surgical excision 1, 4
  • Molecular testing may help identify malignancy in indeterminate cytology samples, but has limitations for FTC 1

Metastatic Pattern

  • FTC characteristically spreads via the hematogenous (blood vessel) route 5, 3
  • This contrasts with PTC, which typically spreads via lymphatic channels 6
  • The hematogenous spread pattern explains why FTC more commonly presents with distant metastases to bone, lung, brain, and liver rather than regional lymph node metastases 5, 6
  • The degree of vascular invasion is a critical prognostic factor and directly correlates with metastatic potential 5, 3

Multifocality

  • FTC is typically unifocal (not multifocal) at presentation 1
  • This contrasts with PTC, which is more commonly multifocal 1
  • The unifocal nature of FTC influences surgical approach decisions 4

Prognostic Factors

  • Key prognostic factors include:
    • Degree of vascular invasion (most important) 5, 3
    • Age (patients <45 years have better outcomes) 5, 6
    • Tumor size 2, 3
    • Presence of distant metastases at diagnosis 2, 3
  • Disease-free survival rates vary significantly based on invasion pattern:
    • Minimally invasive (capsular only): 97% 5
    • Angioinvasive: 81% 5, 3
    • Widely invasive: 46% 5, 3

Treatment Implications

  • The hematogenous spread pattern and unifocal nature of FTC influence treatment decisions 5, 4
  • Total thyroidectomy followed by radioactive iodine ablation is recommended for most FTC cases, especially those with vascular invasion 5, 4
  • Patients with minimally invasive FTC without vascular invasion may be candidates for more conservative surgery (lobectomy) 5, 4
  • Long-term surveillance should focus on detecting distant metastases rather than regional recurrence 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of follicular thyroid carcinoma.

European thyroid journal, 2024

Research

Follicular thyroid carcinoma.

Current treatment options in oncology, 2002

Research

Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2011

Research

Follicular thyroid cancer.

Endocrinology and metabolism clinics of North America, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.